Sopharma AD (BUL:SFA)

Bulgaria · Delayed Price · Currency is BGN · Price in EUR

1.730

+0.015 (0.87%)

At close: Apr 27, 2026

-11.42% (1Y)

Market Cap	1.74B
Revenue (ttm)	2.63B
Net Income (ttm)	133.52M
Shares Out	525.53M
EPS (ttm)	0.39
PE Ratio	8.53
Forward PE	n/a
Dividend	0.06 (1.66%)
Ex-Dividend Date	Dec 18, 2025

Volume	61,725
Average Volume	45,769
Open	1.720
Previous Close	1.715
Day's Range	1.690 - 1.735
52-Week Range	1.410 - 2.900
Beta	0.11
RSI	43.23
Earnings Date	Apr 30, 2026

About Sopharma AD

Sopharma AD produces, distributes, and exports pharmaceutical products in Europe, Bulgaria, and internationally. It offers Carsil to treat liver disease; Tempalgin, a painkiller; Analgin, a pain reliever; Tabex, a drug used for smoking secession; Tribestan, a drug used for stimulation of the male reproductive system; Broncholytin, which is used to suppress cough; Nivalin for use in the peripheral nervous system; Methylprednisolon for severe allergies and life-threatening conditions; Vitamin C; Valeriana to reduce the stress; and medical devices... [Read more]

Industry Pharmaceutical Preparations

Founded 1933

Employees 5,932

Stock Exchange Bulgarian Stock Exchange

Ticker Symbol SFA

Full Company Profile

Financial Performance

In 2025, Sopharma AD's revenue was 2.63 billion, an increase of 22.57% compared to the previous year's 2.15 billion. Earnings were 133.52 million, an increase of 74.97%.

Financial Statements

News

There is no news available yet.